Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 56.87

-2.3%

Dec 5 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (9457)	11/11/2003 6:11:39 PM
From: Icebrg	Read Replies (1) of 52153

>> After I evaluated the data, it became clear that the doses required, the frequency of dosing, and possibly the cost of goods associated with CX516 relegate it to a compound that can be a proof of principle, but not a viable therapeutic agent. >> Dr. Stoll has actually also stressed the fact that CX516 will be "dead in the water" at the two investor's conferences where he has participated in during the autumn. Much to the chagrin of some of the posters over at Yahoo. But to compensate for the fact that CX516 will go nowhere they are probably also not aware of the fact that Organon's Org 24448 may indeed only be a year (or so) from phase III. Provided there is a happy landing with the on-going phase II trials. Erik

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next